Furthermore, a subgroup analysis was conducted considering various clinical and pathological factors related to LUAD and it was found that PP2A protein levels exhibited a decrease in LUAD clinical stages 1 to 3 and tumor grades 2 to 3 compared with normal samples (Fig. 7E). This evidence concerns the gene PTPA and neoplasm.